Skip to main content
Journal cover image

A multimarker multi-time point-based risk stratification strategy in acute heart failure: results from the RELAX-AHF trial.

Publication ,  Journal Article
Demissei, BG; Cotter, G; Prescott, MF; Felker, GM; Filippatos, G; Greenberg, BH; Pang, PS; Ponikowski, P; Severin, TM; Wang, Y; Qian, M ...
Published in: Eur J Heart Fail
August 2017

AIMS: We evaluated the added prognostic value of a multi-time point-based multimarker panel of biomarkers in patients with acute heart failure (AHF). METHODS AND RESULTS: Seven circulating biomarkers [NT-proBNP, high sensitivity cardiac troponin T (hs-cTnT), soluble ST2 (sST2), growth differentiation factor 15 (GDF-15), cystatin-C, galectin-3, and high sensitivity C-reactive protein (hs-CRP)] were measured at baseline and on days 2, 5, 14, and 60 in 1161 patients enrolled in the RELAX-AHF trial. Patients with BNP ≥350 ng/L or NT-proBNP ≥1400 ng/L, mild to moderate renal impairment, and systolic blood pressure >125 mmHg were included in the trial. Time-dependent Cox regression analysis was utilized to evaluate the incremental value of serial measurement of biomarkers. Added value of individual biomarkers and their combination, on top of a pre-specified baseline model, was quantified with the gain in the C-index. Serial biomarker evaluation showed incremental predictive value over baseline measurements alone for the prediction of 180-day cardiovascular mortality except for galectin-3. While a repeat measurement as early as day 2 was adequate for NT-proBNP and cystatin-C in terms of maximizing discriminatory accuracy, further measurements on days 14 and 60 provided added value for hs-cTnT, GDF-15, sST2, and hs-CRP. Individual biomarker additions on top of the baseline model showed additional prognostic value. The greatest prognostic gain was, however, attained with the combination of NT-proBNP, hs-cTnT, GDF-15, and sST2, which yielded 0.08 unit absolute increment in the C-index to 0.87 (95% confidence interval 0.83-0.91]. CONCLUSION: In patients with AHF and mild to moderate renal impairment, a multimarker approach based on a panel of serially evaluated biomarkers provides the greatest prognostic improvement unmatched by a single time point-based single marker strategy.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Eur J Heart Fail

DOI

EISSN

1879-0844

Publication Date

August 2017

Volume

19

Issue

8

Start / End Page

1001 / 1010

Location

England

Related Subject Headings

  • United States
  • Troponin T
  • Survival Rate
  • Risk Factors
  • Risk Assessment
  • Relaxin
  • Recombinant Proteins
  • Prospective Studies
  • Prognosis
  • Peptide Fragments
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Demissei, B. G., Cotter, G., Prescott, M. F., Felker, G. M., Filippatos, G., Greenberg, B. H., … Voors, A. A. (2017). A multimarker multi-time point-based risk stratification strategy in acute heart failure: results from the RELAX-AHF trial. Eur J Heart Fail, 19(8), 1001–1010. https://doi.org/10.1002/ejhf.749
Demissei, Biniyam G., Gad Cotter, Margaret F. Prescott, G Michael Felker, Gerasimos Filippatos, Barry H. Greenberg, Peter S. Pang, et al. “A multimarker multi-time point-based risk stratification strategy in acute heart failure: results from the RELAX-AHF trial.Eur J Heart Fail 19, no. 8 (August 2017): 1001–10. https://doi.org/10.1002/ejhf.749.
Demissei BG, Cotter G, Prescott MF, Felker GM, Filippatos G, Greenberg BH, et al. A multimarker multi-time point-based risk stratification strategy in acute heart failure: results from the RELAX-AHF trial. Eur J Heart Fail. 2017 Aug;19(8):1001–10.
Demissei, Biniyam G., et al. “A multimarker multi-time point-based risk stratification strategy in acute heart failure: results from the RELAX-AHF trial.Eur J Heart Fail, vol. 19, no. 8, Aug. 2017, pp. 1001–10. Pubmed, doi:10.1002/ejhf.749.
Demissei BG, Cotter G, Prescott MF, Felker GM, Filippatos G, Greenberg BH, Pang PS, Ponikowski P, Severin TM, Wang Y, Qian M, Teerlink JR, Metra M, Davison BA, Voors AA. A multimarker multi-time point-based risk stratification strategy in acute heart failure: results from the RELAX-AHF trial. Eur J Heart Fail. 2017 Aug;19(8):1001–1010.
Journal cover image

Published In

Eur J Heart Fail

DOI

EISSN

1879-0844

Publication Date

August 2017

Volume

19

Issue

8

Start / End Page

1001 / 1010

Location

England

Related Subject Headings

  • United States
  • Troponin T
  • Survival Rate
  • Risk Factors
  • Risk Assessment
  • Relaxin
  • Recombinant Proteins
  • Prospective Studies
  • Prognosis
  • Peptide Fragments